About this episode
In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:Brief overview of BTC and GEAApproved HER2-directed therapies for BTC and GEA and their mechanisms of actionEfficacy and toxicities of the approved agents and optimal management strategiesKey ongoing trials of HER2-directed therapies in BTC and GEAChallenges faced by healthcare professionals in the management of patients with BTC and/or GEA PresentersAmit Mahipal, MD, MPHDirector, Gastrointestinal Medical Oncology ProgramRuth and Donald Goodman Endowed Chair in GI OncologyProfessor of Medicine, Senior Attending PhysicianUniversity Hospitals Siedman Cancer CenterCase Comprehensive Cancer CenterCase Western Reserve UniversityCleveland, OhioShubham Pant, MDProfessorDepartment of Gastrointestinal (GI) Medical OncologyDepartment of Investigational Cancer TherapeuticsDirector of Clinical ResearchAssociate Director for Early Phase Drug DevelopmentSheikh Ahmed Bin Zayed Al Nahyan CenterMD Anderson Cancer CenterHouston, TexasLink to full program:https://bit.ly/3KL2ank Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
